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Aims
Noonan syndrome (NS) (MIM 163950) is an autosomal
dominant disorder characterized by postnatal short
stature, congenital heart disease, early feeding difficulties,
mild learning disabilities, and characteristic facial dys-
morphisms, short and webbed neck, and chest deformities.
Proportionate short stature is well recognized as one of
the key features of NS and has been reported in more
than 80% of patients affected by NS. The objective of this
study was to evaluate the efficacy of recombinant human
growth hormone (rhGH) therapy and the influence of
genotype on the response to rhGH therapy in children
with Noonan syndrome (NS).
Methods
Fourteen male and four female subjects with NS with
short stature whose height was less than third percentile,
were included. The rhGH was subcutaneously adminis-
tered at a dose of 66 μg/kg/day, subcutaneously for a
12-month period. Mutations in the PTPN11 gene were
identified in 10 subjects (55.6%). Mutations in the SOS1
(two children, 11.1%), MEK1 (one child, 5.6%) and KRAS
(one child, 5.6%) genes were also found.
Results
The mean age was 8.3±2.4 years (range, 4.4 to 13.2 years)
at the start of rhGH treatment. Height-SDS increased
from -2.8±0.9 at the start of rhGH therapy to -2.0±0.9 12
months later (P<0.001). Height velocity increased from 5.0
±0.9 cm/year in the year before treatment to 8.9±1.6
during treatment (P<0.001). Changes in height SDS,
height velocity, and serum IGF-1 level did not differ signif-
icantly between those children with or without PTPN11
mutations.
Conclusion
The rhGH therapy significantly improved the growth
velocity and increased the serum IGF-1 level. Long-term
correlation between genotype and rhGH therapy respon-
siveness needs to be addressed in a large population.
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